可切除胃癌中微卫星不稳定性与性别差异——三项欧洲队列的汇总分析
该汇总分析纳入三项欧洲队列的1307例可切除胃或胃食管结合部腺癌患者,分析微卫星不稳定性(MSI)状态与性别对生存的影响。结果显示MSI-high胃癌中男性总生存显著差于女性(5年OS 34.7% vs 69.7%;HR 2.68,95%CI 1.60–4.49;p<0.001),MSI的有利预后价值仅见于女性。
要点
- MSI-high胃癌中男性5年OS为34.7%,低于女性的69.7%(HR 2.68,95%CI 1.60–4.49;p<0.001)。
- 女性MSI-high较MSS/MMRP总生存延长(HR 0.61,95%CI 0.41–0.92;p=0.02)。
- 男性MSI-high与MSS/MMRP总生存无显著差异(HR 1.26,95%CI 0.94–1.69;p=0.12)。
核心结论
- 三项独立队列中,MSI-high胃癌男性的预后显著差于女性。
- MSI的有利预后价值仅见于女性,未见于此项分析中的男性。
- 作者认为这些观察强调肿瘤学中需考虑预后与治疗效应的性别差异。
研究设计与样本
- 汇总分析个体患者数据,来源为科隆一项回顾性队列及随机III期临床试验D1/D2和CRITICS。
- 纳入可切除胃和/或胃食管结合部腺癌患者,接受单纯手术或围手术期化疗(放疗)。
- 通过聚合酶链反应(PCR)检测MSI状态和/或免疫组织化学检测错配修复(MMR)状态。
- 共分析1307例肿瘤,其中1192例(91.2%)为MSS和/或MMRP,115例(8.8%)为MSI-high。
主要发现
- MSS/MMRP组中位年龄65岁,男性759例(63.7%),单纯手术619例(51.9%)。
- MSI-high组中位年龄69岁,男性67例(58.3%),单纯手术76例(66.1%)。
- MSI-high胃癌男性5年OS为34.7%,女性为69.7%(HR 2.68,95%CI 1.60–4.49;p<0.001)。
- 女性MSI-high较MSS/MMRP总生存延长(HR 0.61,95%CI 0.41–0.92;p=0.02)。
- 男性MSI-high较MSS/MMRP总生存无显著差异(HR 1.26,95%CI 0.94–1.69;p=0.12)。
关键数值与推荐
- MSI状态由PCR检测和/或MMR状态由免疫组织化学检测判定。
- 共1307例肿瘤中1192例(91.2%)为MSS和/或MMRP,115例(8.8%)为MSI-high。
临床怎么用
- 作者认为这些观察强调肿瘤学中需考虑预后与治疗效应的性别差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Biological sex differences in cancer are increasingly acknowledged. Here, we examined these differences in clinicopathological characteristics and survival in microsatellite instability (MSI)-high and microsatellite stable (MSS) gastric cancer (GC). DESIGN: We analysed MSI status by polymerase chain reaction (PCR) and/or mismatch repair (MMR) status by immunohistochemistry in a pooled analysis of individual patient data from one retrospective cohort from Cologne, and the randomised phase III clinical trials D1/D2 and CRITICS. All patients had resectable adenocarcinoma of the stomach and/or gastro-oesophageal junction. Patients were treated with either surgery only or perioperative chemo(radio)therapy. RESULTS: MSI and/or MMR analyses on 1307 tumours resulted in 1192 (91.2%) MSS and/or MMR proficient (MMRP) [median age, 65 years; 759 males (63.7%); 619 treated with surgery only (51.9%)], and 115 (8.8%) MSI-high [median age, 69 years; 67 males (58.3%); 76 treated with surgery only (66.1%)] GC cases. Males had shorter overall survival (OS) than female MSI-high GC (5-year OS 34.7% vs. 69.7%; hazard ratio (HR) 2.68, 95%CI 1.60 to 4.49; p < 0.001). Females with MSI-high had longer OS than those with MSS/MMRP GC (HR 0.61, 95%CI 0.41 to 0.92; p = 0.02). Males with MSI-high did not have longer OS than those with MSS/MMRP GC (HR 1.26, 95%CI 0.94 to 1.69; p = 0.12). CONCLUSIONS: MSI-high GC males had a significantly worse prognosis compared to their female counterparts in three independent cohorts. In addition, the favourable prognostic value of MSI was only seen in females and not in males. These observations emphasise the need to consider sex differences in prognosis and treatment effects in oncology. CLINICAL TRIAL REGISTRATION: The CRITICS trial is registered at ClinicalTrials.gov, number NCT00407186; EudraCT, number 2006-004130-32; and CKTO, 2006-02.
引用
- Quaas A, Biesma HD, Wagner AD, et al. Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohorts. Eur J Cancer. 2022. PMID: 35863110. doi:10.1016/j.ejca.2022.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。